An insight into the discovery, clinical studies, compositions, and patents of macozinone: A drug targeting the DprE1 enzyme of Mycobacterium tuberculosis

MLA

Mohd. Imran, et al. “An Insight into the Discovery, Clinical Studies, Compositions, and Patents of Macozinone: A Drug Targeting the DprE1 Enzyme of Mycobacterium Tuberculosis.” Journal of Infection and Public Health, vol. 15, no. 10, Oct. 2022, pp. 1097–107. EBSCOhost, https://doi.org/10.1016/j.jiph.2022.08.016.

APA

Mohd. Imran, Shah Alam Khan, Syed Mohammed Basheeruddin Asdaq, Mazen Almehmadi, Osama Abdulaziz, Mehnaz Kamal, Mohammed Kanan Alshammari, Lojain Ibrahim Alsubaihi, Khansa Hamza Hussain, Abrar Saleh Alharbi, & A. Khuzaim Alzahrani. (2022). An insight into the discovery, clinical studies, compositions, and patents of macozinone: A drug targeting the DprE1 enzyme of Mycobacterium tuberculosis. Journal of Infection and Public Health, 15(10), 1097–1107. https://doi.org/10.1016/j.jiph.2022.08.016

Chicago

Mohd. Imran, Shah Alam Khan, Syed Mohammed Basheeruddin Asdaq, Mazen Almehmadi, Osama Abdulaziz, Mehnaz Kamal, Mohammed Kanan Alshammari, et al. 2022. “An Insight into the Discovery, Clinical Studies, Compositions, and Patents of Macozinone: A Drug Targeting the DprE1 Enzyme of Mycobacterium Tuberculosis.” Journal of Infection and Public Health 15 (10): 1097–1107. doi:10.1016/j.jiph.2022.08.016.